In the second- or later-line setting, single-agent pembrolizumab or nivolumab showed clinical activity in patients with PD-L1–positive cervical cancer in single-arm clinical trials (8–10); based on these results, both checkpoint inhibitors have been included in treatment recommendations (11). The gene discussed is CD274; the disease is cervical carcinoma.